I-Abrocitinib ngumlomo, i-molecule encinci, i-Janus kinase (JAK) i-1 inhibitor ekuphuhlisweni kwonyango lwabantu abadala kunye nolutsha olunomodareyitha ukuya kwi-atopic dermatitis enzima.

I-Abrocitinib iphantsi kophando kulingo lwezonyango NCT03796676 (JAK1 Inhibitor Nge-Medicated Topical Therapy kwi-Adolescents kunye ne-Atopic Dermatitis).

I-Abrocitinib okwangoku iphuhliswa yi-Pfizer kunyango lwe-atopic dermatitis (eczema). Yi-inhibitor yophando yomlomo kanye ngosuku i-Janus kinase 1 (JAK1).

I-atopic dermatitis (AD) sisifo solusu esintsonkothileyo, esingapheliyo, esidumbayo esibonakala ngokurhawuzelela, ukurhawuzelelwa kakhulu, kunye nezilonda ze-eczematous ezichaphazela malunga ne-25% yabantwana kunye ne-2% ukuya kwi-3% yabantu abadala kwihlabathi jikelele. I-Abrocitinib yi-inhibitor ekhethiweyo ye-enzyme ye-Janus kinase-1 (JAK1) evimbela inkqubo yokuvuvukala. Ngoko ke, sijonge ukuvavanya ukusebenza kunye nokhuseleko lwe-abrocitinib ye-AD ephakathi ukuya kwi-AD.

I-Abrocitinib kwi-dose ye-100 mg okanye i-200 mg iyiyeza elisebenzayo, elinyamezelwa kakuhle, kwaye lithembisa ukunyanga izigulane ezine-atopic dermatitis ephakathi ukuya kwi-atopic. Nangona kunjalo, uhlalutyo luthande ukusebenza kwe-abrocitinib 200 mg ngaphezu kwe-100 mg, kodwa iziphumo ebezingalindelekanga ezifana nesicaphucaphu kunye nentloko ebuhlungu kusenokwenzeka ukuba zenzeke ngakumbi nge-200 mg.